Literature DB >> 6631214

Presence of two forms of apolipoprotein B in patients with dyslipoproteinemia.

M S Meng, R E Gregg, E J Schaefer, J M Hoeg, H B Brewer.   

Abstract

Current information suggests that the major forms of the human B apolipoproteins, B-100 and B-48, are under separate genetic control and are synthesized by the liver and intestine, respectively. The apolipoprotein B composition of plasma lipoproteins has been determined in order to gain insight into the metabolic defects in patients with dyslipoproteinemias. Patients with type I and type V hyperlipoproteinemia can be separated into two groups based on apolipoprotein composition and triglyceride concentration. The first group had markedly elevated plasma triglycerides with B-48 in the 1.006 g/ml density fraction and only B-100 within IDL and LDL. The second group had plasma triglycerides less than 1200 mg % and only B-100 in all density fractions. Patients with type III hyperlipoproteinemia had B-48 in only the density less than 1.006 g/ml with B-100 in IDL and LDL; the type III hyperlipoproteinemic patient with apolipoprotein E deficiency, however, had B-48 in density less than 1.006 g/ml fraction, IDL, and LDL. Patients with type IIa, IIb, and IV hyperlipoproteinemia had only B-100 in all density fractions. These combined results are interpreted as indicating that B-48 is associated with triglyceride-rich lipoproteins synthesized by the intestine and that patients with phenotypes I, III, and V have defects in chylomicron remnant metabolism. In addition, in patients with types I and V hyperlipoproteinemia, mild hypertriglyceridemia appears to be associated with lipoprotein particles of liver origin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631214

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  4 in total

1.  Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects.

Authors:  D C Rubinsztein; J C Cohen; G M Berger; D R van der Westhuyzen; G A Coetzee; W Gevers
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

Review 2.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

3.  Familial apolipoprotein E deficiency.

Authors:  E J Schaefer; R E Gregg; G Ghiselli; T M Forte; J M Ordovas; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

4.  Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.

Authors:  C J Packard; A Munro; A R Lorimer; A M Gotto; J Shepherd
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.